Medicus Pharma (MDCXW) Total Current Liabilities (2023 - 2025)
Medicus Pharma (MDCXW) reported Total Current Liabilities of $9.9 million for Q4 2025, up 330.92% on a YoY basis from $2.3 million in Q4 2024, and down 6.75% quarter-over-quarter from $10.7 million in Q3 2025.
Medicus Pharma (MDCXW) Total Current Liabilities (2023 - 2025) Analysis & Trends
Medicus Pharma has reported Total Current Liabilities for 3 years, with the latest figure at $9.9 million in Q4 2025.
- For the quarter ending Q4 2025, Total Current Liabilities rose 330.92% year-over-year to $9.9 million; the trailing twelve-month figure through Dec 2025 stood at $9.9 million (up 330.92% YoY), and the FY2025 full-year result was $9.9 million, up 330.92% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $9.9 million, down from $10.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $10.7 million in Q3 2025, with the low at $781609.0 in Q4 2023.
- Historically, Total Current Liabilities has averaged $5.9 million across 3 years, with a median of $5.9 million in 2025.
- Annual changes were most pronounced in 2024 — Total Current Liabilities surged 195.06% — and 2025, when it surged 330.92%.
- Medicus Pharma's Total Current Liabilities stood at $781609.0 in 2023, then jumped by 195.06% to $2.3 million in 2024, then surged by 330.92% to $9.9 million in 2025.
- The last three Total Current Liabilities figures came in at $9.9 million (Q4 2025), $10.7 million (Q3 2025), and $8.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -30.24 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 36.63 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 57.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 42.10 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 19.16 Bn |
| 10 | Medicus Pharma | - | - | - | 9.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.94 Mn |
| Sep 30, 2025 | 10.66 Mn |
| Jun 30, 2025 | 8.54 Mn |
| Mar 31, 2025 | 3.34 Mn |
| Dec 31, 2024 | 2.31 Mn |
| Dec 31, 2023 | 781,609.00 |